Holding company for Samsung Bioepis, which develops and sells biosimilar drugs worldwide.
Holding company for Samsung Bioepis, which develops and sells biosimilar drugs worldwide.
Holds Samsung Bioepis, which sells biosimilars, near-copies of biologic drugs whose patents have expired, mostly through commercial partners in the US and Europe that handle sales. Bioepis is the main earner. Epis was split out as a holding company from Samsung Biologics in 2025.
In one line: A holding company over a Sandoz-style biosimilar maker.
Moat: narrow (regulatory licence, process know-how). Biosimilar approvals and manufacturing scale-up are costly barriers for new entrants.
Headquarters: Incheon, South Korea · Founded: 2025 · Employees: 9
Size Samsung Epis (0126Z0.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $6.49B, the 64th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩362,500 on 18 Nov 2026.
Performance Over six months the shares fell 31.2%, against -4.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth The operating margin is 12.4% (peer median 15.8%).
Valuation It trades at 23.8× forward earnings against a peer median of 21.9× (8th cheapest of 15).
Capital Return on invested capital runs 3.7 points below its cost of capital (5.8% WACC).
Next results Next results expected around 1 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | |
|---|---|---|
| Revenue | ₩1.54T | ₩252B |
| Revenue growth | — | — |
| Gross profit | n/a | ₩88.6B |
| EBITDA | n/a | ₩5.34B |
| Net income | ₩250B | -₩31.4B |
| Free cash flow | n/a | -₩110B |
| Capital expenditure | n/a | ₩40.0B |
| Total debt | ₩607B | ₩378B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Samsung Epis 0126Z0.KS | $6.49B | -31% | n/a | 12% | 23.8× | n/a |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Celltrion 068270.KS | $34.9B | +12% | +40% | 32% | 33.9× | 10.6% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0126Z0.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.2% | -2.1% | 3rd highest of 21 |
| 6-month return | -31.2% | -4.5% | 4th lowest of 20 |
| Distance from 52-week high | -53.1% | -20.5% | 2nd lowest of 21 |
| Operating margin | 12.4% | 15.8% | 8th lowest of 19 |
| Forward P/E | 23.8× | 21.9× | 8th cheapest of 15 |
| ROIC minus cost of capital | -3.7 pp | +2.2 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |